These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27034789)

  • 1. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.
    Chuong MD; Frakes JM; Figura N; Hoffe SE; Shridhar R; Mellon EA; Hodul PJ; Malafa MP; Springett GM; Centeno BA
    J Gastrointest Oncol; 2016 Apr; 7(2):221-7. PubMed ID: 27034789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
    Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
    Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer.
    Zakem SJ; Mueller AC; Meguid C; Torphy RJ; Holt DE; Schefter T; Messersmith WA; McCarter MD; Del Chiaro M; Schulick RD; Goodman KA
    HPB (Oxford); 2021 Jul; 23(7):1072-1083. PubMed ID: 33277184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
    Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
    Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
    Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
    J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection.
    Reddy AV; Hill CS; Sehgal S; Ding D; Hacker-Prietz A; He J; Zheng L; Herman JM; Meyer J; Narang AK
    Radiat Oncol J; 2021 Dec; 39(4):304-314. PubMed ID: 34986552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.
    Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
    J Gastrointest Oncol; 2022 Feb; 13(1):368-379. PubMed ID: 35284125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.
    Mellon EA; Strom TJ; Hoffe SE; Frakes JM; Springett GM; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    J Gastrointest Oncol; 2016 Aug; 7(4):547-55. PubMed ID: 27563444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
    Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
    Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: influence of vascular margin status and type of chemotherapy.
    Palm RF; Boyer E; Kim DW; Denbo J; Hodul PJ; Malafa M; Fleming JB; Shridhar R; Chuong MD; Mellon EA; Frakes JM; Hoffe SE
    HPB (Oxford); 2023 Sep; 25(9):1110-1120. PubMed ID: 37286392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy.
    Chung EM; Lu DJ; Nguyen AT; Hendifar AE; Nissen NN; Gong J; Osipov A; Gangi A; Attiyeh MA; Atkins KM; Kamrava M
    Adv Radiat Oncol; 2024 May; 9(5):101471. PubMed ID: 38550374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database.
    Zhu X; Li F; Liu W; Shi D; Ju X; Cao Y; Shen Y; Cao F; Qing S; Fang F; Jia Z; Zhang H
    Cancer Manag Res; 2018; 10():1295-1304. PubMed ID: 29872342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era.
    Abi Jaoude J; Thunshelle CP; Kouzy R; Nguyen ND; Lin D; Prakash L; Bumanlag IM; Noticewala SS; Niedzielski JS; Beddar S; Ludmir EB; Holliday EB; Das P; Minsky BD; Herman JM; Katz M; Koong AC; Koay EJ; Taniguchi CM
    Adv Radiat Oncol; 2021; 6(6):100763. PubMed ID: 34934858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
    Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
    J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
    Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
    PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.